Abstract
Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Current Drug Discovery Technologies
Title: Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity
Volume: 4 Issue: 1
Author(s): Jeffrey Wang and Ying Huang
Affiliation:
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Abstract: Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Export Options
About this article
Cite this article as:
Jeffrey Wang and Ying Huang , Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity, Current Drug Discovery Technologies 2007; 4(1) . https://dx.doi.org/10.2174/157016307781115485
DOI https://dx.doi.org/10.2174/157016307781115485 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia A Modified Teaching-Learning-Based Optimization (mTLBO) for Global Search
Recent Patents on Computer Science The Determination and Use of Optimized Protease Substrates In Drug Discovery and Development
Current Pharmaceutical Design Effects of Some Metal Ions on Human Erythrocyte Glutathione Reductase:An In Vitro Study
Protein & Peptide Letters Editorial (Thematic Issue: “Discovery and Development of New Anticancer Drugs Inspired from Natural Product Leads” Part 2)
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: ErbB Family and Downstream Signal Transduction Pathways as Targets for Anticancer Therapy (Guest Editor: F. Caponigro)]
Current Drug Targets Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Systems Biology Approaches in Identifying the Targets of Natural Compounds for Cancer Therapy
Current Drug Discovery Technologies Lipid Oxidation Products in the Pathogenesis of Inflammation-related Gut Diseases
Current Medicinal Chemistry Synthesis and Anti – Tumour Activity of Novel Camptothecin – Bile Acid Analogues
Letters in Drug Design & Discovery Align: a C++ Class Library and Web Server for Rapid Sequence Alignment Prototyping
Current Drug Discovery Technologies Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism Cell Contact/Adhesion Proteins Lgl and DFak56: Tumorigenic and Whole-Organism Vital Effects Studied in Drosophila
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Essential Oils as Active Ingredients of Lipid Nanocarriers for Chemotherapeutic Use
Current Pharmaceutical Biotechnology Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols
Medicinal Chemistry Reviews - Online (Discontinued) Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design